规则全面优化,第十一批国家组织药品集采今日开标
Sou Hu Cai Jing·2025-10-27 00:19

Core Points - The 11th batch of national organized drug procurement has commenced bidding, with results expected later today. The procurement rules have been comprehensively optimized to adhere to principles of "stabilizing clinical use, ensuring quality, preventing internal competition, and avoiding collusion" [1][3] Group 1: Clinical Stability - The reporting method for medical institutions has been optimized, allowing them to report either by generic name or specific brand. Among 46,000 medical institutions, 77% reported by brand, facilitating procurement results that better reflect actual clinical medication needs [1] - Special rules for antibiotics and pediatric formulations have been improved to ensure stable clinical supply [1] Group 2: Quality Assurance - Increased focus on the quality control levels of enterprises, raising the quality threshold for bidding. Requirements include actual production experience and a clean record of inspections for the past two years [3] - Selected drugs will be subject to enhanced supervision and inspection by drug regulatory authorities, ensuring comprehensive coverage of both selected enterprises and products [3] Group 3: Market Competition - The price difference control mechanism has been optimized, introducing "revival for inclusion" and "revival for non-inclusion" mechanisms to guide healthy market competition. Each enterprise must commit to pricing not lower than their costs, with lower-priced enterprises required to justify their pricing [3] Group 4: Anti-Collusion Measures - Measures have been implemented to restrict enterprises with related interests, treating them as a single entity to prevent collusion in pricing. A "first report leniency" mechanism is being explored to dismantle alliances among colluding enterprises [3] - According to the latest revised medical pricing and procurement credit evaluation system, collusion and bid-rigging behaviors will be severely penalized, with companies facing significant restrictions on their product listing qualifications [3]